EA200701978A1 - Способ получения опиоидных модуляторов - Google Patents

Способ получения опиоидных модуляторов

Info

Publication number
EA200701978A1
EA200701978A1 EA200701978A EA200701978A EA200701978A1 EA 200701978 A1 EA200701978 A1 EA 200701978A1 EA 200701978 A EA200701978 A EA 200701978A EA 200701978 A EA200701978 A EA 200701978A EA 200701978 A1 EA200701978 A1 EA 200701978A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
opioid modulators
modulators
opioid
agonists
Prior art date
Application number
EA200701978A
Other languages
English (en)
Other versions
EA015512B1 (ru
Inventor
Чаочжун Цай
Вей Хе
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36646011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA200701978A1 publication Critical patent/EA200701978A1/ru
Publication of EA015512B1 publication Critical patent/EA015512B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к новым способам получения опиоидных модуляторов (агонистов и антагонистов) и промежуточных продуктов их синтеза. Опиоидные модуляторы применяют при лечении и профилактике как боли, так и желудочно-кишечных нарушений.
EA200701978A 2005-03-14 2006-03-06 Способ получения опиоидных модуляторов EA015512B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66178405P 2005-03-14 2005-03-14
PCT/US2006/008450 WO2006099060A2 (en) 2005-03-14 2006-03-06 Process for the preparation of opioid modulators

Publications (2)

Publication Number Publication Date
EA200701978A1 true EA200701978A1 (ru) 2008-04-28
EA015512B1 EA015512B1 (ru) 2011-08-30

Family

ID=36646011

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200701978A EA015512B1 (ru) 2005-03-14 2006-03-06 Способ получения опиоидных модуляторов
EA200701979A EA014366B1 (ru) 2005-03-14 2006-03-06 Способ получения опиоидных модуляторов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200701979A EA014366B1 (ru) 2005-03-14 2006-03-06 Способ получения опиоидных модуляторов

Country Status (30)

Country Link
US (4) US7629488B2 (ru)
EP (2) EP1858850B1 (ru)
JP (3) JP5384933B2 (ru)
KR (2) KR20070112255A (ru)
CN (2) CN101175725B (ru)
AR (2) AR053170A1 (ru)
AU (2) AU2006223394B2 (ru)
BR (2) BRPI0607792A2 (ru)
CA (2) CA2601674A1 (ru)
CR (1) CR9438A (ru)
CY (1) CY1116104T1 (ru)
DK (1) DK1858850T3 (ru)
EA (2) EA015512B1 (ru)
ES (1) ES2535048T3 (ru)
HR (1) HRP20150417T1 (ru)
HU (1) HUE024912T2 (ru)
IL (3) IL185974A0 (ru)
ME (1) ME02110B (ru)
MX (2) MX2007011412A (ru)
MY (1) MY145333A (ru)
NI (1) NI200700237A (ru)
NO (2) NO340604B1 (ru)
NZ (1) NZ590570A (ru)
PL (1) PL1858850T3 (ru)
PT (1) PT1858850E (ru)
RS (1) RS53873B1 (ru)
SI (1) SI1858850T1 (ru)
TW (3) TWI500595B (ru)
WO (2) WO2006099060A2 (ru)
ZA (2) ZA200708809B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
ME02221B (me) * 2004-03-15 2016-02-20 Janssen Pharmaceutica Nv Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora
KR20070112255A (ko) * 2005-03-14 2007-11-22 얀센 파마슈티카 엔.브이. 오피오이드 조절체의 제조 방법
HUE028538T2 (en) * 2007-07-09 2016-12-28 Forest Tosara Ltd New Crystals and Procedure 5 - ({[2-Amino-3- (4-carbamoyl-2,6-dimethylphenyl) propionyl] - [1- (4-phenyl-1H-imidazol-2-yl) ethyl] ] -amino} -methyl) -2-methoxybenzoic acid
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US10822308B2 (en) * 2016-06-23 2020-11-03 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
CN106866463B (zh) * 2017-01-24 2018-08-28 富乐马鸿凯（大连）医药有限公司 艾沙度林中间体的制备方法
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
US20230312542A1 (en) 2020-03-31 2023-10-05 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法
CN114507252B (zh) * 2022-02-21 2023-10-27 广西大学 新型芳基硅烷化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430129A (en) * 1977-08-09 1979-03-06 Mitsubishi Gas Chem Co Inc Preparation of toluic acid amide
JPS5528959A (en) * 1978-08-22 1980-02-29 Sumitomo Chem Co Ltd Production of amide derivative
FR2584401B1 (fr) * 1985-07-04 1987-11-20 Ile De France Nouveau benzamide, son procede de preparation et son application dans le domaine therapeutique
JP2727243B2 (ja) * 1988-12-27 1998-03-11 日本化薬株式会社 ２−アシルアミノ桂皮酸誘導体の製造法
US5684175A (en) * 1993-02-05 1997-11-04 Napro Biotherapeutics, Inc. C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
JP3493206B2 (ja) * 1993-03-19 2004-02-03 ダイセル化学工業株式会社 光学活性β−アミノ酸類の製法
JP3486922B2 (ja) * 1993-08-23 2004-01-13 住友化学工業株式会社 酸アミドの製造法
MX9705710A (es) * 1995-01-27 1997-10-31 Novo Nordisk As Compuestos con propiedades de liberacion de la hormona del crecimiento.
JPH09295939A (ja) * 1995-09-26 1997-11-18 Takeda Chem Ind Ltd リン酸アミド誘導体、その製造法および用途
OA11901A (en) * 1998-03-11 2006-04-10 Searle & Co Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
DE60006032T2 (de) * 1999-05-28 2004-06-17 Pfizer Products Inc., Groton 3-(3-Hydroxyphenyl)-3-amino-propionamidderivate
CA2422617C (en) * 2000-10-30 2011-07-12 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
ME02221B (me) * 2004-03-15 2016-02-20 Janssen Pharmaceutica Nv Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora
KR20070112255A (ko) * 2005-03-14 2007-11-22 얀센 파마슈티카 엔.브이. 오피오이드 조절체의 제조 방법

Also Published As

Publication number Publication date
US20060211863A1 (en) 2006-09-21
PL1858850T3 (pl) 2015-06-30
ZA200708810B (en) 2009-01-28
IL209402A (en) 2015-06-30
HUE024912T2 (en) 2016-02-29
AU2006223394A1 (en) 2006-09-21
WO2006099060A2 (en) 2006-09-21
AU2006223394B2 (en) 2012-10-18
JP2013234192A (ja) 2013-11-21
NZ590570A (en) 2012-06-29
AR054745A1 (es) 2007-07-11
ES2535048T3 (es) 2015-05-04
US20060211861A1 (en) 2006-09-21
IL185972A (en) 2013-07-31
WO2006099060A3 (en) 2006-11-02
US20100152460A1 (en) 2010-06-17
EP1858850B1 (en) 2015-01-21
EA200701979A1 (ru) 2008-04-28
JP5802242B2 (ja) 2015-10-28
HRP20150417T1 (en) 2015-09-25
CA2601481A1 (en) 2006-09-21
CA2601674A1 (en) 2006-09-21
JP5384933B2 (ja) 2014-01-08
RS53873B1 (en) 2015-08-31
JP2008533143A (ja) 2008-08-21
AR053170A1 (es) 2007-04-25
BRPI0607793A2 (pt) 2009-06-13
NO20075268L (no) 2007-12-10
JP2008533141A (ja) 2008-08-21
IL185972A0 (en) 2008-01-06
TW201302676A (zh) 2013-01-16
NI200700237A (es) 2008-06-25
ME02110B (me) 2015-10-20
KR101280929B1 (ko) 2013-07-01
TWI414518B (zh) 2013-11-11
MX2007011412A (es) 2008-02-22
CN101175725B (zh) 2011-02-02
TWI500595B (zh) 2015-09-21
EP1863764A1 (en) 2007-12-12
TW200700388A (en) 2007-01-01
IL209402A0 (en) 2011-01-31
TW200716548A (en) 2007-05-01
CN101175726A (zh) 2008-05-07
BRPI0607792A2 (pt) 2009-06-13
CN101175725A (zh) 2008-05-07
MX2007011409A (es) 2008-02-22
US20100036132A1 (en) 2010-02-11
CR9438A (es) 2008-09-09
IL185974A0 (en) 2008-01-06
KR20070116067A (ko) 2007-12-06
EA015512B1 (ru) 2011-08-30
KR20070112255A (ko) 2007-11-22
EA014366B1 (ru) 2010-10-29
US7629488B2 (en) 2009-12-08
PT1858850E (pt) 2015-02-24
WO2006098982A1 (en) 2006-09-21
MY145333A (en) 2012-01-31
ZA200708809B (en) 2009-03-25
NO340604B1 (no) 2017-05-15
DK1858850T3 (en) 2015-02-09
CY1116104T1 (el) 2017-02-08
SI1858850T1 (sl) 2015-04-30
EP1858850A2 (en) 2007-11-28
NO20075269L (no) 2007-12-10
AU2006223482A1 (en) 2006-09-21
CA2601481C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
EA200701978A1 (ru) Способ получения опиоидных модуляторов
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
MA32975B1 (fr) Antagonistes de c5ar
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
NO20055741L (no) Nye kjemiske forbindelser
ATE469897T1 (de) Indazolcarbonsäureamidverbindungen
MY147217A (en) Antibody molecules having specificity for human il-06
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
EA201190313A1 (ru) Замещенные пиперидины
ATE450256T1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
EA200801211A1 (ru) Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение
EA201001872A1 (ru) Новые способы получения производных циклопропиламида
EA200970122A1 (ru) Фармацевтически приемлемые солевые и полиморфные формы малеата флюпиртина
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
EA200700191A1 (ru) Композиции, содержащие никорандил, способ получения и применение